MedTrace Logo

Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia

NCT00824512 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2020-04-07

Study results available
· View outcomes & findings →

Summary

The purpose of this protocol is to determine the efficacy of EGb 761 120 mg bid versus placebo in patients suffering from Friedreich Ataxia

Conditions

  • Friedreich Ataxia

Interventions

DRUG

EGb 761 120 mg

EGb 761® 120 mg bid, orally for 12 to 14 weeks

DRUG

Placebo

Placebo 1 tablet BID, orally for 12 to 14 weeks

Sponsors & Collaborators

Principal Investigators

  • Ipsen Medical Director · Ipsen

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00824512 on ClinicalTrials.gov